Cargando…

Identification of active Plasmodium falciparum calpain to establish screening system for Pf-calpain-based drug development

BACKGROUND: With the increasing resistance of malaria parasites to available drugs, there is an urgent demand to develop new anti-malarial drugs. Calpain inhibitor, ALLN, is proposed to inhibit parasite proliferation by suppressing haemoglobin degradation. This provides Plasmodium calpain as a poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Soh, Byoung Yul, Song, Hyun-Ok, Lee, Yoonji, Lee, Junghyun, Kaewintajuk, Kusuma, Lee, Binna, Choi, Yun-Young, Cho, Jeong Hoon, Choi, Sun, Park, Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583800/
https://www.ncbi.nlm.nih.gov/pubmed/23374507
http://dx.doi.org/10.1186/1475-2875-12-47
_version_ 1782475482267123712
author Soh, Byoung Yul
Song, Hyun-Ok
Lee, Yoonji
Lee, Junghyun
Kaewintajuk, Kusuma
Lee, Binna
Choi, Yun-Young
Cho, Jeong Hoon
Choi, Sun
Park, Hyun
author_facet Soh, Byoung Yul
Song, Hyun-Ok
Lee, Yoonji
Lee, Junghyun
Kaewintajuk, Kusuma
Lee, Binna
Choi, Yun-Young
Cho, Jeong Hoon
Choi, Sun
Park, Hyun
author_sort Soh, Byoung Yul
collection PubMed
description BACKGROUND: With the increasing resistance of malaria parasites to available drugs, there is an urgent demand to develop new anti-malarial drugs. Calpain inhibitor, ALLN, is proposed to inhibit parasite proliferation by suppressing haemoglobin degradation. This provides Plasmodium calpain as a potential target for drug development. Pf-calpain, a cysteine protease of Plasmodium falciparum, belongs to calpain-7 family, which is an atypical calpain not harboring Ca(2+)-binding regulatory motifs. In this present study, in order to establish the screening system for Pf-calpain specific inhibitors, the active form of Pf-calpain was first identified. METHODS: Recombinant Pf-calpain including catalytic subdomain IIa (rPfcal-IIa) was heterologously expressed and purified. Enzymatic activity was determined by both fluorogenic substrate assay and gelatin zymography. Molecular homology modeling was carried out to address the activation mode of Pf-calpain in the aspect of structural moiety. RESULTS: Based on the measurement of enzymatic activity and protease inhibitor assay, it was found that the active form of Pf-calpain only contains the catalytic subdomain IIa, suggesting that Pf-calpain may function as a monomeric form. The sequence prediction indicates that the catalytic subdomain IIa contains all amino acid residues necessary for catalytic triad (Cys-His-Asn) formation. Molecular modeling suggests that the Pf-calpain subdomain IIa makes an active site, holding the catalytic triad residues in their appropriate orientation for catalysis. The mutation analysis further supports that those amino acid residues are functional and have enzymatic activity. CONCLUSION: The identified active form of Pf-calpain could be utilized to establish high-throughput screening system for Pf-calpain inhibitors. Due to its unique monomeric structural property, Pf-calpain could be served as a novel anti-malarial drug target, which has a high specificity for malaria parasite. In addition, the monomeric form of enzyme may contribute to relatively simple synthesis of selective inhibitors.
format Online
Article
Text
id pubmed-3583800
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35838002013-02-28 Identification of active Plasmodium falciparum calpain to establish screening system for Pf-calpain-based drug development Soh, Byoung Yul Song, Hyun-Ok Lee, Yoonji Lee, Junghyun Kaewintajuk, Kusuma Lee, Binna Choi, Yun-Young Cho, Jeong Hoon Choi, Sun Park, Hyun Malar J Research BACKGROUND: With the increasing resistance of malaria parasites to available drugs, there is an urgent demand to develop new anti-malarial drugs. Calpain inhibitor, ALLN, is proposed to inhibit parasite proliferation by suppressing haemoglobin degradation. This provides Plasmodium calpain as a potential target for drug development. Pf-calpain, a cysteine protease of Plasmodium falciparum, belongs to calpain-7 family, which is an atypical calpain not harboring Ca(2+)-binding regulatory motifs. In this present study, in order to establish the screening system for Pf-calpain specific inhibitors, the active form of Pf-calpain was first identified. METHODS: Recombinant Pf-calpain including catalytic subdomain IIa (rPfcal-IIa) was heterologously expressed and purified. Enzymatic activity was determined by both fluorogenic substrate assay and gelatin zymography. Molecular homology modeling was carried out to address the activation mode of Pf-calpain in the aspect of structural moiety. RESULTS: Based on the measurement of enzymatic activity and protease inhibitor assay, it was found that the active form of Pf-calpain only contains the catalytic subdomain IIa, suggesting that Pf-calpain may function as a monomeric form. The sequence prediction indicates that the catalytic subdomain IIa contains all amino acid residues necessary for catalytic triad (Cys-His-Asn) formation. Molecular modeling suggests that the Pf-calpain subdomain IIa makes an active site, holding the catalytic triad residues in their appropriate orientation for catalysis. The mutation analysis further supports that those amino acid residues are functional and have enzymatic activity. CONCLUSION: The identified active form of Pf-calpain could be utilized to establish high-throughput screening system for Pf-calpain inhibitors. Due to its unique monomeric structural property, Pf-calpain could be served as a novel anti-malarial drug target, which has a high specificity for malaria parasite. In addition, the monomeric form of enzyme may contribute to relatively simple synthesis of selective inhibitors. BioMed Central 2013-02-04 /pmc/articles/PMC3583800/ /pubmed/23374507 http://dx.doi.org/10.1186/1475-2875-12-47 Text en Copyright ©2013 Soh et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Soh, Byoung Yul
Song, Hyun-Ok
Lee, Yoonji
Lee, Junghyun
Kaewintajuk, Kusuma
Lee, Binna
Choi, Yun-Young
Cho, Jeong Hoon
Choi, Sun
Park, Hyun
Identification of active Plasmodium falciparum calpain to establish screening system for Pf-calpain-based drug development
title Identification of active Plasmodium falciparum calpain to establish screening system for Pf-calpain-based drug development
title_full Identification of active Plasmodium falciparum calpain to establish screening system for Pf-calpain-based drug development
title_fullStr Identification of active Plasmodium falciparum calpain to establish screening system for Pf-calpain-based drug development
title_full_unstemmed Identification of active Plasmodium falciparum calpain to establish screening system for Pf-calpain-based drug development
title_short Identification of active Plasmodium falciparum calpain to establish screening system for Pf-calpain-based drug development
title_sort identification of active plasmodium falciparum calpain to establish screening system for pf-calpain-based drug development
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583800/
https://www.ncbi.nlm.nih.gov/pubmed/23374507
http://dx.doi.org/10.1186/1475-2875-12-47
work_keys_str_mv AT sohbyoungyul identificationofactiveplasmodiumfalciparumcalpaintoestablishscreeningsystemforpfcalpainbaseddrugdevelopment
AT songhyunok identificationofactiveplasmodiumfalciparumcalpaintoestablishscreeningsystemforpfcalpainbaseddrugdevelopment
AT leeyoonji identificationofactiveplasmodiumfalciparumcalpaintoestablishscreeningsystemforpfcalpainbaseddrugdevelopment
AT leejunghyun identificationofactiveplasmodiumfalciparumcalpaintoestablishscreeningsystemforpfcalpainbaseddrugdevelopment
AT kaewintajukkusuma identificationofactiveplasmodiumfalciparumcalpaintoestablishscreeningsystemforpfcalpainbaseddrugdevelopment
AT leebinna identificationofactiveplasmodiumfalciparumcalpaintoestablishscreeningsystemforpfcalpainbaseddrugdevelopment
AT choiyunyoung identificationofactiveplasmodiumfalciparumcalpaintoestablishscreeningsystemforpfcalpainbaseddrugdevelopment
AT chojeonghoon identificationofactiveplasmodiumfalciparumcalpaintoestablishscreeningsystemforpfcalpainbaseddrugdevelopment
AT choisun identificationofactiveplasmodiumfalciparumcalpaintoestablishscreeningsystemforpfcalpainbaseddrugdevelopment
AT parkhyun identificationofactiveplasmodiumfalciparumcalpaintoestablishscreeningsystemforpfcalpainbaseddrugdevelopment